BrightPath Biotherapeutics
4594.TTSE GROWTHPharmaceutical
Filed as BrightPath Biotherapeutics Co., Ltd (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2018-03 | 2017-03 | 2016-03 |
|---|---|---|---|
| Revenue | ¥354m | ¥530m | — |
| Operating income | −¥1.6bn | −¥1.1bn | — |
| Ordinary income | −¥1.6bn | −¥1.1bn | — |
| Net income (owners) | −¥1.6bn | −¥1.1bn | — |
| Total assets | ¥7.2bn | ¥5.4bn | — |
| Net assets / equity | ¥7.0bn | ¥5.2bn | ¥2.7bn |
| Operating cash flow | −¥1.6bn | −¥1.1bn | — |
| EPS (basic) | ¥-41.25 | ¥-32.74 | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 5
| Period | Form | Figures |
|---|---|---|
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 44 figures · EDINET |
| 2021-04-01 → 2022-03-31 | AnnualAmended | 117 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 66 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 42 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 117 figures · EDINET |
21 more reports are still being processed.